fosun pharma internationalization new milestone product of yao pharma breaking into the us market-凯发k8娱乐app下载

fosun pharma internationalization new milestone product of yao pharma breaking into the us market-凯发k8娱乐app下载


fosun pharma internationalization new milestone product of yao pharma breaking into the us market

【8 september 2016, hong kong】on 7 september, 2016, yao pharma, a subsidiary company of shanghai fosun pharmaceutical (group) co., ltd. (“fosun pharma”; stock code:, celebrated the export of its self-invented formulation product – venlafaxine tablet, its first product registered in the united states, to the us market for the first time. this makes yao pharma one of the leading pharmaceutical enterprises in china exporting formulation products to the us market. it is also the only pharmaceutical enterprise pioneering in such export in west china. this is another important achievement made by yao pharma in practicing its internationalization strategy, after the export of its quetiapine fumarate extended-release tablets to canada in 2015, and is a milestone for yao pharma as well as fosun pharma in their internationalization process.


the venlafaxine tablet is a psychotropic drug with anti-anxiety and anti-depression effects. the drug is primarily used in treatment of various depressions such as agitated depression and generalized anxiety disorder. since its introduction 22 years ago, the drug has stable therapeutic effect, and has been one of the top priority drugs for patients suffering from depression. therefore, this drug has a promising outlook in europe and the us.

the launch of yao pharma’s product in the us reflects that the formulation product manufactured by yao pharma has fully met the quality standard of developed countries. moreover, the product also offers a “chinese alternative” for patients suffering from depression in europe and the us. the barriers for chinese pharmaceutical enterprises entering into domestic and overseas pharmaceutical markets have been broken down. in particular, valuable experience in the export of high-end formulation has been gained.


in an interview, liu qiang, the senior vice president of fosun pharmaceutical industrial and chairman of yao pharma, said, “as a pioneer in the internationalization among pharmaceutical enterprises in west china, yao pharma always believes that development in leaps and bounds is possible only when we go globally through internationalization to explore the regulated and developed international market with higher profitability by capitalizing on the edge of the advanced management and technology abroad. ”


fosun pharma is one of the first enterprises in the prc pharmaceutical industry to practice internationalization strategy. its production has expanded overseas with several production lines recognized by relevant international certifications, and some of the formulations and apis have also entered into the international markets in a considerable scale. at present, 13 apis of fosun pharma received gmp certifications from national health departments such as the us fda, the european union, ministry of health, labor and welfare of japan and federal ministry of health of germany. 1 production line for oral solid dosage formulation, 3 production lines for injection and 5 apis of guilin pharma have passed the who-pq examination, and 1 production line of oral solid dosage formulation of yao pharma has been recognized by canada health and the us fda. fosun pharma has become the leading provider and researcher of anti-malaria medicines in the world. in the future, fosun pharma will continue to adhere to its brand philosophy of “innovation for good health”. while implementing its internationalization strategy by exporting chinese products to developed countries, fosun pharma also endeavors to provide safe, convenient and high quality healthcare products and services to the patients in china, thus sparing no effort in improving the human health quality.


about chongqing yao pharmaceutical company limited

as a subsidiary company of fosun pharma, chongqing yao pharmaceutical company limited (“yao pharma”) is a pharmaceutical manufacturer with integrated r&d, manufacturing and marketing & sales functions. it is located in chongqing, an industrial hub in southwestern part of china. priding itself in a history of nearly 80 years in pharmaceutical manufacturing, yao pharma strives to be a leading company in this industry.

presently, yao pharma products are manufactured in one api manufacturing site and four finished dosage form manufacturing sites. yao pharma has established a rigorous quality assurance system, based on the concept of “quality by design”. many of its api production lines passed gmp inspections from us fda, edqm, german health authority, japan pmda and brazil anvisa, etc. its oral solid production line passed gmp inspections from health canada and us fda. two of its anda products have been approved by health canada and us fda respectively.

looking into the future, yao pharma will continue to develop high-quality and innovative pharmaceuticals for the benefit of general public.



about shanghai fosun pharmaceutical (group) co.,ltd.

established in 1994, shanghai fosun pharmaceutical (group) co., ltd. (“fosun pharma”; stock code:, is a leading healthcare group in the prc. fosun pharma strategically covers important segments of the healthcare industry value-chain, including pharmaceutical manufacturing and r&d, healthcare services, medical diagnosis, medical devices manufacturing and agent, as well as pharmaceutical distribution and retail, making contribution to improving people’s health. fosun pharma maintains a national recognized enterprise technology centre and a highly capable international r&d team, focusing on innovation and research of therapeutic areas including cardiovascular system, central nervous system, blood system, metabolism and digestive tract system, anti-infection and anti-tumor. with its commitment to innovation for good health and creating a better future, fosun pharma will continue insisting on the strategic development approach of “organic growth with external expansion and integrated business operation”, striving to be one of the first-class enterprises in the global healthcare market.